An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
Latest Information Update: 08 Aug 2024
At a glance
- Drugs NNZ 2591 (Primary)
- Indications Prader-Willi syndrome
- Focus Adverse reactions; Pharmacokinetics
- Acronyms PWS-001
- Sponsors Neuren Pharmaceuticals
- 06 Aug 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.
- 06 Aug 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2025.
- 03 Jun 2024 Status changed from recruiting to discontinued.